axitinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 4225 319460-85-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • axitinib
  • inlyta
  • AG 013736
  • AG-013736
A benzamide and indazole derivative that acts as a TYROSINE KINASE inhibitor of the VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR. It is used in the treatment of advanced RENAL CELL CARCINOMA.
  • Molecular weight: 386.47
  • Formula: C22H18N4OS
  • CLOGP: 3.19
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 70.67
  • ALOGS: -5.85
  • ROTB: 5

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
10 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Hosey CM, Chan R, Benet LZ
CL (Clearance) 5 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.00 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 4.30 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 0.00 mg/mL Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
Jan. 27, 2012 FDA PFIZER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neoplasm progression 606.52 23.51 212 7838 36216 63444756
Diarrhoea 346.84 23.51 436 7614 714930 62766042
Disease progression 305.38 23.51 191 7859 122567 63358405
Death 291.56 23.51 293 7757 374088 63106884
Hypertension 223.10 23.51 222 7828 279081 63201891
Palmar-plantar erythrodysaesthesia syndrome 218.55 23.51 89 7961 22926 63458046
Dysphonia 181.69 23.51 98 7952 47516 63433456
Decreased appetite 149.53 23.51 171 7879 250881 63230091
Stomatitis 140.42 23.51 126 7924 138599 63342373
Blood pressure increased 134.85 23.51 132 7918 161930 63319042
Fatigue 123.21 23.51 314 7736 887714 62593258
Hypothyroidism 92.43 23.51 61 7989 42571 63438401
Oral pain 90.60 23.51 52 7998 28342 63452630
Drug ineffective 66.51 23.51 25 8025 1044740 62436232
Off label use 64.25 23.51 209 7841 674253 62806719
Dehydration 56.33 23.51 88 7962 173266 63307706
Nausea 56.32 23.51 235 7815 854236 62626736
Posterior reversible encephalopathy syndrome 50.64 23.51 30 8020 17315 63463657
Weight decreased 48.83 23.51 108 7942 276690 63204282
Proteinuria 42.94 23.51 28 8022 19117 63461855
Immune-mediated hepatic disorder 40.39 23.51 10 8040 505 63480467
Polycythaemia 39.20 23.51 11 8039 904 63480068
Asthenia 35.52 23.51 118 7932 383486 63097486
Constipation 33.30 23.51 82 7968 224861 63256111
Oligodipsia 30.14 23.51 5 8045 30 63480942
Drug hypersensitivity 28.75 23.51 3 8047 310684 63170288
Malignant neoplasm progression 27.05 23.51 42 8008 82079 63398893
Hyperkeratosis 24.63 23.51 13 8037 6005 63474967
Second primary malignancy 23.85 23.51 14 8036 7939 63473033

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neoplasm progression 1278.46 19.50 485 19457 22815 34914174
Dysphonia 1133.82 19.50 445 19497 22938 34914051
Disease progression 793.07 19.50 582 19360 107495 34829494
Diarrhoea 696.78 19.50 971 18971 388941 34548048
Hypertension 512.35 19.50 500 19442 135943 34801046
Fatigue 493.01 19.50 806 19136 369847 34567142
Death 461.11 19.50 814 19128 397235 34539754
Palmar-plantar erythrodysaesthesia syndrome 361.23 19.50 181 19761 16614 34920375
Decreased appetite 314.33 19.50 428 19514 165964 34771025
Blood pressure increased 268.22 19.50 289 19653 87813 34849176
Stomatitis 223.99 19.50 189 19753 42325 34894664
Oral pain 168.29 19.50 94 19848 10733 34926256
Hypothyroidism 164.68 19.50 118 19824 20784 34916205
Aphonia 151.85 19.50 61 19881 3312 34933677
Drug ineffective 141.29 19.50 43 19899 456708 34480281
Glossodynia 133.16 19.50 57 19885 3636 34933353
Weight decreased 108.08 19.50 280 19662 176021 34760968
Immune-mediated hepatic disorder 96.75 19.50 32 19910 991 34935998
Dry skin 76.86 19.50 92 19850 31195 34905794
Proteinuria 74.52 19.50 71 19871 18571 34918418
Blister 67.60 19.50 74 19868 22784 34914205
Dry mouth 66.50 19.50 84 19858 30081 34906908
Nausea 66.40 19.50 374 19568 339534 34597455
Pain in extremity 57.89 19.50 181 19761 126332 34810657
Febrile neutropenia 56.80 19.50 6 19936 136843 34800146
Thyroid disorder 55.98 19.50 30 19912 3152 34933837
Neutropenia 55.54 19.50 11 19931 156767 34780222
Blood pressure abnormal 55.33 19.50 42 19900 8064 34928925
Product dose omission in error 53.26 19.50 26 19916 2248 34934741
Second primary malignancy 51.93 19.50 40 19902 7846 34929143
Drug interaction 49.81 19.50 34 19908 225912 34711077
Constipation 49.44 19.50 181 19761 136801 34800188
Oral discomfort 49.43 19.50 26 19916 2631 34934358
Taste disorder 48.67 19.50 37 19905 7118 34929871
Off label use 48.08 19.50 405 19537 419119 34517870
Product dose omission issue 45.58 19.50 161 19781 119550 34817439
Asthenia 44.57 19.50 265 19677 244986 34692003
Toxicity to various agents 44.35 19.50 30 19912 200332 34736657
Overdose 40.45 19.50 3 19939 91056 34845933
Therapy interrupted 39.89 19.50 44 19898 13653 34923336
Pneumonia 39.05 19.50 94 19848 362533 34574456
Thrombocytopenia 36.47 19.50 22 19920 156225 34780764
Blood thyroid stimulating hormone increased 35.74 19.50 25 19917 4230 34932759
Adrenal insufficiency 35.62 19.50 42 19900 14005 34922984
Anaemia 35.32 19.50 49 19893 233286 34703703
Tongue discomfort 33.95 19.50 13 19929 620 34936369
Body surface area decreased 33.74 19.50 6 19936 8 34936981
Pancytopenia 33.00 19.50 7 19935 95150 34841839
Headache 31.53 19.50 209 19733 200426 34736563
Oropharyngeal pain 28.81 19.50 63 19879 35422 34901567
Skin exfoliation 28.57 19.50 54 19888 27378 34909611
Cardiac arrest 26.23 19.50 11 19931 96148 34840841
Rhabdomyolysis 25.82 19.50 4 19938 68159 34868830
Osteonecrosis of jaw 24.87 19.50 40 19902 17849 34919140
Dehydration 23.24 19.50 140 19802 129829 34807160
Protein urine present 22.98 19.50 21 19921 5207 34931782
Oral mucosal blistering 22.89 19.50 14 19928 1888 34935101
Hepatic function abnormal 22.61 19.50 66 19876 44297 34892692
Hyperkeratosis 22.49 19.50 18 19924 3731 34933258
Posterior reversible encephalopathy syndrome 22.37 19.50 28 19914 9926 34927063
Thyroid function test abnormal 22.30 19.50 10 19932 713 34936276
Multiple organ dysfunction syndrome 22.13 19.50 8 19934 76558 34860431
Nephrectomy 21.35 19.50 10 19932 788 34936201
Drug hypersensitivity 20.73 19.50 10 19932 80519 34856470
Abdominal discomfort 20.64 19.50 78 19864 59757 34877232
Pyrexia 20.59 19.50 109 19833 332904 34604085
Tremor 20.15 19.50 11 19931 82576 34854413
Illness 19.84 19.50 31 19911 13498 34923491
Abdominal pain upper 19.75 19.50 87 19855 71403 34865586
Hospice care 19.70 19.50 22 19920 6918 34930071

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neoplasm progression 1793.44 19.43 667 26058 51015 79666648
Dysphonia 1213.07 19.43 517 26208 56355 79661308
Disease progression 1012.68 19.43 677 26048 183685 79533978
Diarrhoea 954.36 19.43 1308 25417 879181 78838482
Death 821.85 19.43 975 25750 565539 79152124
Hypertension 635.46 19.43 661 26064 330331 79387332
Fatigue 572.69 19.43 1070 25655 928657 78789006
Palmar-plantar erythrodysaesthesia syndrome 546.96 19.43 252 26473 32882 79684781
Decreased appetite 463.91 19.43 571 26154 341847 79375816
Blood pressure increased 372.32 19.43 404 26321 210956 79506707
Stomatitis 276.61 19.43 291 26434 146466 79571197
Oral pain 236.71 19.43 142 26583 31656 79686007
Hypothyroidism 231.67 19.43 169 26556 52223 79665440
Drug ineffective 205.36 19.43 55 26670 1080858 78636805
Weight decreased 163.02 19.43 364 26361 354834 79362829
Immune-mediated hepatic disorder 146.26 19.43 43 26682 1551 79716112
Aphonia 144.13 19.43 70 26655 10242 79707421
Proteinuria 102.70 19.43 86 26639 32416 79685247
Dry skin 97.36 19.43 117 26608 67878 79649785
Off label use 91.08 19.43 566 26159 906649 78811014
Constipation 89.54 19.43 252 26473 282798 79434865
Asthenia 86.76 19.43 370 26355 511319 79206344
Nausea 83.17 19.43 576 26149 956620 78761043
Product dose omission issue 77.88 19.43 220 26505 247317 79470346
Blood pressure abnormal 72.71 19.43 54 26671 17115 79700548
Drug hypersensitivity 72.12 19.43 8 26717 298908 79418755
Second primary malignancy 69.59 19.43 49 26676 14301 79703362
Taste disorder 67.53 19.43 50 26675 15773 79701890
Dry mouth 67.05 19.43 112 26613 87907 79629756
Product dose omission in error 63.74 19.43 37 26688 7751 79709912
Dehydration 63.38 19.43 205 26520 247982 79469681
Thyroid disorder 58.99 19.43 44 26681 14035 79703628
Febrile neutropenia 58.82 19.43 5 26720 230994 79486669
Toxicity to various agents 56.26 19.43 36 26689 421504 79296159
Blood thyroid stimulating hormone increased 51.42 19.43 35 26690 9673 79707990
Adrenal insufficiency 50.90 19.43 55 26670 28432 79689231
Drug interaction 49.46 19.43 40 26685 415143 79302520
Oral discomfort 48.89 19.43 34 26691 9726 79707937
Pain in extremity 47.94 19.43 245 26480 364293 79353370
Hyperkeratosis 45.87 19.43 30 26695 7760 79709903
Skin exfoliation 45.86 19.43 73 26652 55027 79662636
Blister 45.42 19.43 114 26611 119362 79598301
Polycythaemia 42.80 19.43 19 26706 2265 79715398
Treatment failure 42.55 19.43 4 26721 170482 79547181
Hepatic function abnormal 41.62 19.43 82 26643 73025 79644638
Body surface area decreased 41.21 19.43 8 26717 43 79717620
Posterior reversible encephalopathy syndrome 40.54 19.43 47 26678 26234 79691429
Overdose 39.55 19.43 7 26718 184199 79533464
Joint swelling 39.38 19.43 24 26701 288622 79429041
Malignant neoplasm progression 38.98 19.43 117 26608 135873 79581790
Pancytopenia 38.56 19.43 5 26720 165740 79551923
Tongue discomfort 38.38 19.43 18 26707 2435 79715228
Neutropenia 37.77 19.43 25 26700 287685 79429978
Renal impairment 37.26 19.43 127 26598 157656 79560007
Arthropathy 35.37 19.43 8 26717 177103 79540560
Rheumatoid arthritis 35.07 19.43 13 26712 208457 79509206
Oral mucosal blistering 34.21 19.43 23 26702 6228 79711435
Hospice care 34.02 19.43 28 26697 10296 79707367
Pneumonia 33.24 19.43 112 26613 660134 79057529
Sinusitis 33.20 19.43 12 26713 195489 79522174
Thyroiditis 32.79 19.43 20 26705 4585 79713078
Renal cancer 31.86 19.43 29 26696 12197 79705466
Osteonecrosis of jaw 30.26 19.43 53 26672 43173 79674490
Hyperthyroidism 29.79 19.43 37 26688 22172 79695491
Nephrectomy 28.48 19.43 14 26711 2101 79715562
Wheezing 28.42 19.43 3 26722 116661 79601002
Protein urine present 28.36 19.43 25 26700 10087 79707576
Nephrotic syndrome 28.14 19.43 26 26699 11148 79706515
Cancer pain 27.99 19.43 19 26706 5226 79712437
Thrombocytopenia 27.48 19.43 29 26696 265230 79452433
Cardiac arrest 26.88 19.43 12 26713 172084 79545579
Feeding disorder 26.64 19.43 30 26695 16224 79701439
Condition aggravated 26.58 19.43 83 26642 501041 79216622
Renal cell carcinoma 26.32 19.43 20 26705 6558 79711105
Oligodipsia 25.43 19.43 5 26720 29 79717634
Asthma 25.23 19.43 7 26718 135088 79582575
Hypersensitivity 24.64 19.43 31 26694 262208 79455455
Hepatic cytolysis 24.02 19.43 37 26688 27114 79690549
Eating disorder 23.88 19.43 32 26693 20665 79696998
Agitation 23.20 19.43 3 26722 99712 79617951
Pemphigus 23.16 19.43 3 26722 99579 79618084
Bronchitis 22.21 19.43 8 26717 130636 79587027
Dysgeusia 22.18 19.43 55 26670 57122 79660541
Anaemia 22.01 19.43 76 26649 444939 79272724
Pyrexia 21.67 19.43 136 26589 678573 79039090
Immune-mediated renal disorder 21.25 19.43 6 26719 187 79717476
Ageusia 21.18 19.43 27 26698 16605 79701058
Blood corticotrophin increased 21.09 19.43 6 26719 192 79717471
Immune-mediated hypothyroidism 20.89 19.43 8 26717 655 79717008
Syncope 20.46 19.43 18 26707 179431 79538232
Weight increased 20.14 19.43 39 26686 277347 79440316
Oropharyngeal pain 19.93 19.43 81 26644 109272 79608391
Cardiac dysfunction 19.80 19.43 14 26711 4110 79713553
Immune-mediated myocarditis 19.72 19.43 9 26716 1144 79716519

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01EK01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
FDA MoA N0000020000 Receptor Tyrosine Kinase Inhibitors
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D047428 Protein Kinase Inhibitors
FDA EPC N0000175605 Kinase Inhibitor
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:38637 tyrosine kinase inhibitors
CHEBI has role CHEBI:65207 vascular endothelial growth factor receptor inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Renal cell carcinoma indication 702391001 DOID:4450




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.57 acidic
pKa2 12.18 acidic
pKa3 4.85 Basic
pKa4 1.98 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
1MG INLYTA PF PRISM CV N202324 Jan. 27, 2012 RX TABLET ORAL 10570202 Feb. 3, 2035 IN COMBINATION WITH PEMBROLIZUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
5MG INLYTA PF PRISM CV N202324 Jan. 27, 2012 RX TABLET ORAL 10570202 Feb. 3, 2035 IN COMBINATION WITH PEMBROLIZUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
1MG INLYTA PF PRISM CV N202324 Jan. 27, 2012 RX TABLET ORAL 10869924 Jan. 12, 2037 AXITINIB IN COMBINATION WITH AVELUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
5MG INLYTA PF PRISM CV N202324 Jan. 27, 2012 RX TABLET ORAL 10869924 Jan. 12, 2037 AXITINIB IN COMBINATION WITH AVELUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Vascular endothelial growth factor receptor 3 Kinase INHIBITOR Kd 6.77 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 1 Kinase INHIBITOR Kd 8.24 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 2 Kinase INHIBITOR Kd 8.23 CHEMBL CHEMBL
Mast/stem cell growth factor receptor Kit Kinase Kd 9.31 CHEMBL
Epidermal growth factor receptor Kinase Kd 5.64 CHEMBL
Breakpoint cluster region protein Kinase Kd 6.73 CHEMBL
Tyrosine-protein kinase Lck Kinase Kd 5.57 CHEMBL
Tyrosine-protein kinase Yes Kinase Kd 5.57 CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase Kd 7.51 CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase Kd 7 CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase Kd 7.68 CHEMBL
Platelet-derived growth factor receptor alpha Kinase Kd 9.29 CHEMBL
Mitogen-activated protein kinase 8 Kinase Kd 5.41 CHEMBL
Fibroblast growth factor receptor 3 Kinase Kd 6.68 CHEMBL
Mitogen-activated protein kinase 10 Kinase Kd 5.96 CHEMBL
High affinity nerve growth factor receptor Kinase Kd 5.74 CHEMBL
Tyrosine-protein kinase JAK2 Kinase Kd 5.48 CHEMBL
Myosin light chain kinase 2, skeletal/cardiac muscle Kinase Kd 5.89 CHEMBL
Tyrosine-protein kinase CSK Kinase Kd 5.96 CHEMBL
Angiopoietin-1 receptor Kinase Kd 6.51 CHEMBL
AP2-associated protein kinase 1 Kinase Kd 5.92 CHEMBL
Hepatocyte growth factor receptor Kinase Kd 6.09 CHEMBL
Fibroblast growth factor receptor 1 Kinase Kd 6.42 CHEMBL
Serine/threonine-protein kinase 10 Kinase Kd 5.92 CHEMBL
Serine/threonine-protein kinase PLK4 Kinase Ki 8.38 CHEMBL
Aurora kinase C Kinase Kd 8.89 CHEMBL
Serine/threonine-protein kinase 16 Kinase Kd 6.43 CHEMBL
Dual specificity protein kinase TTK Kinase Kd 5.41 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 7.15 CHEMBL
Fibroblast growth factor receptor 2 Kinase Kd 6.96 CHEMBL
TRAF2 and NCK-interacting protein kinase Kinase Kd 6.74 CHEMBL
Tyrosine-protein kinase Fgr Kinase Kd 5.74 CHEMBL
Aurora kinase A Kinase Kd 7.14 CHEMBL
BMP-2-inducible protein kinase Kinase Kd 6 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5 Kinase Kd 6.26 CHEMBL
Mitogen-activated protein kinase kinase kinase 4 Kinase Kd 5.25 CHEMBL
Cyclin-G-associated kinase Kinase Kd 5.57 CHEMBL
Receptor-interacting serine/threonine-protein kinase 2 Kinase Kd 5 CHEMBL
Cyclin-dependent kinase 16 Kinase Kd 5.28 CHEMBL
Serine/threonine-protein kinase 4 Kinase Kd 5.85 CHEMBL
Activated CDC42 kinase 1 Kinase Kd 5.22 CHEMBL
STE20-like serine/threonine-protein kinase Kinase Kd 6 CHEMBL
Calcium/calmodulin-dependent protein kinase kinase 2 Kinase Kd 5.82 CHEMBL
Calcium/calmodulin-dependent protein kinase kinase 1 Kinase Kd 5.85 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 6.47 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 1 Kinase Kd 5.57 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 2 Kinase Kd 5.59 CHEMBL
Tyrosine-protein kinase ITK/TSK Kinase Kd 5.92 CHEMBL
Tyrosine-protein kinase receptor UFO Kinase Kd 6.38 CHEMBL
Serine/threonine-protein kinase N2 Kinase Kd 5.57 CHEMBL
Serine/threonine-protein kinase 3 Kinase Kd 5.66 CHEMBL
NUAK family SNF1-like kinase 2 Kinase Kd 5.89 CHEMBL
Non-receptor tyrosine-protein kinase TNK1 Kinase Kd 6.80 CHEMBL
Non-receptor tyrosine-protein kinase TYK2 Kinase Kd 5.44 CHEMBL
Mitogen-activated protein kinase kinase kinase MLT Kinase Kd 5.59 CHEMBL
Serine/threonine-protein kinase RIO1 Kinase Kd 5.92 CHEMBL
Tyrosine-protein kinase receptor Tie-1 Kinase Kd 7.01 CHEMBL
Tyrosine-protein kinase TXK Kinase Kd 5.62 CHEMBL
Casein kinase II subunit alpha' Kinase Kd 5.55 CHEMBL
Serine/threonine-protein kinase RIO3 Kinase Kd 6 CHEMBL
SRSF protein kinase 1 Kinase Kd 5.74 CHEMBL
Activin receptor type-2B Kinase Kd 5.28 CHEMBL
Ankyrin repeat and protein kinase domain-containing protein 1 Kinase Kd 5.44 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 5.28 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1 Kinase Kd 6.48 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 3 Kinase Kd 5.92 CHEMBL
Aurora kinase B Kinase Kd 7.96 CHEMBL
Tyrosine-protein kinase Blk Kinase Kd 5.51 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 4 Kinase Kd 6.46 CHEMBL
Tyrosine-protein kinase Mer Kinase Kd 5.49 CHEMBL
Mitogen-activated protein kinase kinase kinase 9 Kinase Kd 5.52 CHEMBL
Serine/threonine-protein kinase MRCK beta Kinase Kd 5.32 CHEMBL
Myosin-IIIa Kinase Kd 5.72 CHEMBL
Serine/threonine-protein kinase PAK 4 Kinase Kd 5.35 CHEMBL
Serine/threonine-protein kinase SIK1 Kinase Kd 5.68 CHEMBL
Dual specificity testis-specific protein kinase 1 Kinase Kd 5.37 CHEMBL
Interferon-induced, double-stranded RNA-activated protein kinase Kinase Kd 5.13 CHEMBL
Receptor-interacting serine/threonine-protein kinase 1 Kinase Kd 5.60 CHEMBL
Proto-oncogene tyrosine-protein kinase ROS Kinase Kd 5.49 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2 Kinase Kd 5.89 CHEMBL
Misshapen-like kinase 1 Kinase Kd 6.25 CHEMBL
Cyclin-dependent kinase-like 2 Kinase Kd 6.28 CHEMBL
Ephrin type-B receptor 6 Kinase Kd 6.44 CHEMBL
G protein-coupled receptor kinase 4 Kinase Kd 5.64 CHEMBL
Hormonally up-regulated neu tumor-associated kinase Kinase Kd 5.82 CHEMBL
Interleukin-1 receptor-associated kinase 1 Kinase Kd 5.51 CHEMBL
Mitogen-activated protein kinase kinase kinase 3 Kinase Kd 5.55 CHEMBL
SRSF protein kinase 3 Kinase Kd 5.64 CHEMBL
Serine/threonine-protein kinase ULK2 Kinase Kd 5 CHEMBL
Serine/threonine-protein kinase ULK3 Kinase Kd 6.17 CHEMBL
Mitogen-activated protein kinase kinase kinase 19 Kinase Kd 6.57 CHEMBL
Receptor-interacting serine/threonine-protein kinase 4 Kinase Kd 5.85 CHEMBL
Bone morphogenetic protein receptor type-1B Kinase Kd 5.54 CHEMBL
Mitogen-activated protein kinase kinase kinase 12 Kinase Kd 5.77 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5 Kinase Kd 6.85 CHEMBL
Myosin light chain kinase 3 Kinase Kd 5.77 CHEMBL
Leucine-rich repeat serine/threonine-protein kinase 2 Kinase Kd 6.04 CHEMBL
Ferrochelatase, mitochondrial Enzyme Kd 5.17 CHEMBL
Tyrosine-protein kinase JAK3 Kinase Kd 5.51 CHEMBL
Uncharacterized protein FLJ45252 Unclassified Kd 5.64 CHEMBL
Platelet-derived growth factor receptor beta Kinase Kd 9.24 CHEMBL
Tyrosine-protein kinase ABL1 Kinase Kd 8.82 CHEMBL

External reference:

IDSource
4031332 VUID
N0000184323 NUI
D03218 KEGG_DRUG
4031332 VANDF
C1700874 UMLSCUI
CHEBI:66910 CHEBI
AXI PDB_CHEM_ID
CHEMBL1289926 ChEMBL_ID
D000077784 MESH_DESCRIPTOR_UI
DB06626 DRUGBANK_ID
5659 IUPHAR_LIGAND_ID
8720 INN_ID
C9LVQ0YUXG UNII
6450551 PUBCHEM_CID
1242999 RXNORM
187097 MMSL
28294 MMSL
d07823 MMSL
014143 NDDF
427882000 SNOMEDCT_US
429507005 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
INLYTA HUMAN PRESCRIPTION DRUG LABEL 1 0069-0145 TABLET, FILM COATED 1 mg ORAL NDA 32 sections
INLYTA HUMAN PRESCRIPTION DRUG LABEL 1 0069-0145 TABLET, FILM COATED 1 mg ORAL NDA 32 sections
INLYTA HUMAN PRESCRIPTION DRUG LABEL 1 0069-0151 TABLET, FILM COATED 5 mg ORAL NDA 32 sections
INLYTA HUMAN PRESCRIPTION DRUG LABEL 1 0069-0151 TABLET, FILM COATED 5 mg ORAL NDA 32 sections
INLYTA HUMAN PRESCRIPTION DRUG LABEL 1 63539-026 TABLET, FILM COATED 1 mg ORAL NDA 32 sections
INLYTA HUMAN PRESCRIPTION DRUG LABEL 1 63539-026 TABLET, FILM COATED 1 mg ORAL NDA 32 sections
INLYTA HUMAN PRESCRIPTION DRUG LABEL 1 63539-044 TABLET, FILM COATED 5 mg ORAL NDA 32 sections
INLYTA HUMAN PRESCRIPTION DRUG LABEL 1 63539-044 TABLET, FILM COATED 5 mg ORAL NDA 32 sections